Chirag Rajyaguru
Advanced Heart Failure and Transplant Cardiology · Palos Park, ILNPI 1326434937
Payments from drug & device makers
What this record shows
This record is dominated by grants: $15,089 of the $18,951 with a category attached, or 79.6%. Medtronic accounts for 80.2% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2021 at $15,240 and has fallen 91.5% since, to $1,295 in 2025.
Across 141 payments — averaging $134.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$15K
- Abbott$795
- AstraZeneca$409
- Novartis$324
- Actelion Pharmaceuticals US, Inc.$309
- Pfizer$275
- plus $2K from 23 others
What the payments were for
- Grants$15,08980%
- Travel & lodging$4082%
- Food & beverage$3,34118%
- Education$1131%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 7 | $15,205 |
| Abbott | 9 | $795 |
| AstraZeneca | 15 | $409 |
| Novartis | 17 | $324 |
| Actelion Pharmaceuticals US, Inc. | 10 | $309 |
| Pfizer | 18 | $275 |
| E.r. Squibb & Sons, L.L.C. | 9 | $245 |
| Novo Nordisk | 5 | $208 |
| United Therapeutics Corporation | 2 | $158 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $107 |
| Bayer | 5 | $104 |
| Merck | 6 | $102 |
| Daiichi Sankyo Inc. | 3 | $84 |
| Boehringer Ingelheim | 3 | $80 |
| Cvrx, Inc. | 4 | $63 |
| GSK | 3 | $62 |
| Bridgebio Pharma, Inc. | 2 | $60 |
| Boston Scientific | 1 | $57 |
| Johnson & Johnson | 3 | $54 |
| Altathera Pharmaceuticals LLC | 1 | $42 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $33 |
| Scpharmaceuticals Inc. | 2 | $33 |
| Abiomed | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Atricure, Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Kestra Medical Technology Services, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$399
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$209
- Ozempic$122
- CAMZYOS$110
- FARXIGA$101
How this compares
$18,951 in reported general payments places this provider in the 60th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
See all advanced heart failure and transplant cardiology providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 36 | $893,968 |
| CamzyosMavacamten | 27 | $222,414 |
| EntrestoSacubitril/Valsartan | 203 | $218,946 |
| FarxigaDapagliflozin Propanediol | 126 | $133,332 |
| JardianceEmpagliflozin | 155 | $127,935 |
| EliquisApixaban | 48 | $40,305 |
| OzempicSemaglutide | 25 | $39,017 |
| Torsemide | 102 | $2,549 |
| Metoprolol Succinate | 108 | $1,016 |
| Spironolactone | 113 | $837 |
| Potassium Chloride | 33 | $538 |
| Losartan Potassium | 42 | $504 |
| Bumetanide | 11 | $444 |
| Nifedipine ErNifedipine | 13 | $420 |
| Furosemide | 97 | $389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $275 | $934,27384 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $245 | $222,41427 claims |
| NovartisEntresto | $324 | $218,946203 claims |
| AstraZenecaFarxiga | $409 | $133,332126 claims |
| Boehringer IngelheimJardiance | $80 | $127,935155 claims |
| Novo NordiskOzempic | $208 | $39,01725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
Other advanced heart failure and transplant cardiology in Palos Park
- Maria Rosa CostanzoNaperville$716K
- Jonathan RichChicago$327K
- Esther VorovichChicago$224K
- Jane WilcoxChicago$220K
- Ali ValikaElmhurst$218K
- Manreet KanwarChicago$162K
- Jonathan GrinsteinChicago$128K
- Muhyaldee DiaOak Lawn$125K
- Bow ChungChicago$86K
- Owais MalickDowners Grove$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.